“Oncodesign’s extensive experience in developing anticancer therapeutics complements BioFocus DPI’s medicinal chemistry and biology expertise, creating a focused oncology drug discovery offering that can move rapidly from hit finding to pre-clinical candidate,” said Chris Newton, Senior Vice President, BioFocus DPI. “As the industry’s understanding of disease pathways has grown considerably in recent years, the need for specialised drug discovery services has also grown. We expect that our current and future customers will benefit greatly from the synergies that this alliance offers.”
“This alliance with BioFocus DPI corresponds with our vision of offering comprehensive drug discovery expertise in the field of oncology,” Oncodesign’s President and CEO, Philippe Genne, stated. “We are extremely pleased to have the opportunity of collaborating with an internationally recognised drug discovery company of BioFocus DPI’s caliber. This, combined with our extensive oncology experience and ongoing drug and biomarker discovery strategy will allow our clients to benefit from fully-integrated target validation to clinical candidate selection services.”
